98168-52-6

Basic information

• Product Name: 1,3-DIELAIDIN
• Synonyms: DELTA 9 TRANS DIELAIDIN 1-3 ISOMER;C18:1,[TRANS]-9;1,3-DIELAIDIN;1,3-DI[TRANS-9-OCTADECENOYL]-GLYCEROL;1,3-DIELAIDIN (C18:1,-TRANS-9);1,3-Dielaidin,1,3-Di(trans-9-octadecenoyl)glycerol
• CAS NO: 98168-52-6
• Molecular Formula: C₃₉H₇₂O₅
• Molecular Weight: 620.99
• Mol File: 98168-52-6.mol
• Article Data: 36

Chemical Properties

• Boiling Point: 678.3°C at 760 mmHg
• Flash Point: 189.2°C
• Appearance: /
• Density: 0.934g/cm³
• Vapor Pressure: 2.58E-21mmHg at 25°C
• Refractive Index: 1.477
• Storage Temp.: −20°C
• CAS DataBase Reference: 1,3-DIELAIDIN(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-DIELAIDIN(98168-52-6)
• EPA Substance Registry System: 1,3-DIELAIDIN(98168-52-6)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 98168-52-6(Hazardous Substances Data)

Usage

Description

1,3-DIELAIDIN, also known as 1,3-Dielaidoyl glycerol, is a diacylglycerol that contains elaidic acid at the sn-1 and sn-3 positions. It is a type of glycerol esterified with two fatty acids, specifically elaidic acid, which is a trans isomer of oleic acid. This unique structure gives 1,3-DIELAIDIN specific properties that make it useful in various applications.

Uses

Used in Gene Transfer Applications:
1,3-DIELAIDIN is used as a component to prepare symmetrical cationic triglycerides, which are essential for gene transfer processes. The cationic nature of these triglycerides allows them to interact with negatively charged nucleic acids, facilitating their delivery into target cells. This makes 1,3-DIELAIDIN a valuable compound in the development of non-viral gene therapy vectors, which are crucial for various medical and biotechnological applications, including the treatment of genetic disorders and certain types of cancer.

InChI:InChI=1/C39H72O5/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-38(41)43-35-37(40)36-44-39(42)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17-20,37,40H,3-16,21-36H2,1-2H3/b19-17+,20-18+

Upstream product

• 112-62-9 Methyl oleate 
• 56-81-5 glycerol 
• 112-80-1 cis-Octadecenoic acid 
• 112-77-6 (Z)-9-octadecenoyl chloride 
• 2716-53-2 1-mono[trans-9-octadecenoyl]-rac-glycerol 
• 143997-01-7 (S)-3-((4-methoxybenzyl)oxy)propane-1,2-diyl dioleate 
• 122-32-7 trioleoylglycerol 
• 24472-44-4 2-oxopropane-1,3-diyl dioleate 
• 111-62-6 oleic acid ethyl ester 
• 62147-49-3 1,3-dihydroxyacetone dimer 
• 3896-58-0 vinyl oleate 
• 2442-61-7 1,2-dioleoylglycerol 
• 111-03-5 1-monooleoyl glycerol 
• 112-79-8 Elaidic Acid 

Downstream Products

• 1716-07-0 1,3-dioleoyl-2-palmitoylglycerol 
• 112-62-9 Methyl oleate 
• 628-13-7 pyridine hydrochloride 
• 148691-24-1 (Z,Z,Z,Z,Z)-icosa-5,8,11,14,17-pentaenoic acid 2-((Z)-octadec-9-enoyloxy)-1-((Z)-octadec-9-enoyloxymethyl)ethyl ester 
• 19229-69-7 Dioleo-β-lecithin 

Relevant articles and documents

Triglyceride-mimetic structure-gated prodrug nanoparticles for smart cancer therapy

Off-target drug release and insufficient drug delivery are the main obstacles for effective anticancer chemotherapy. Prodrug-based self-assembled nanoparticles bioactivated under tumor-specific conditions are one of the effective strategies to achieve on-demand drug release and effective tumor accumulation. Herein, stimuli-activable prodrugs are designed yielding smart tumor delivery by combination of the triglyceride-mimic (TG-mimetic) prodrug structure and disulfide bond. Surprisingly, these prodrugs can self-assemble into uniform nanoparticles (NPs) with a high drug loading (over 40%) and accumulate in tumor sites specifically. The super hydrophobic TG structure can act as a gate that senses lipase to selectively control over NP dissociation and affect the glutathione-triggered prodrug activation. In addition, the impacts of the double bonds in the prodrug NPs on parent drug release and the following cytotoxicity, pharmacokinetics, and antitumor efficiency are further demonstrated. Our findings highlight the promising potential of TG-mimetic structure-gated prodrug nanoparticles for tumor-specific drug delivery.

LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

LIPID PRODRUGS OF GLUCOCORTICOIDS AND USES THEREOF

The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.